Prognostic value of prostaglandin F2 alpha concentrations in breast carcinoma.
Prostaglandin F2 alpha (PGF2 alpha) concentrations were measured by radioimmunoassay in homogenised primary tumours from 57 patients with breast cancer. These patients were followed up from 60 to 78 months (median 63 months) after surgery and PGF2 alpha concentrations were related prospectively to metastatic spread and survival. The amounts of PGF2 alpha varied greatly in the different tumours (range 0-90 ng/mg protein), but no significant association was found between PGF2 alpha concentrations and disease free survival, time of relapse, site of recurrence, or overall survival. It therefore seems unlikely that measurement of PGF2 alpha in breast carcinoma is important in the prognosis of the disease.
van Dam
P A
PA
Department of Gynaecology, St Camillus Hospital (Antwerp University), Belgium.
Vergote
I B
IB
Laekeman
G M
GM
Keersmaeckers
G H
GH
Uyttenbroeck
F L
FL
Herman
A G
AG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001530:Belgium / Q000453:epidemiology; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality; D015237:Dinoprost / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors
D015237:Dinoprost